Delcath Systems has obtained CE mark approval for the second generation hemofiltration cartridge of the company's proprietary hepatic chemosat delivery system.
The new hemofiltration cartridge allows physicians to use the product for the percutaneous intra-arterial administration of a chemotherapeutic agent (melphalan hydrochloride) to the liver of any patient.
Delcath Systems president and CEO Eamonn Hobbs said the new hemofiltration cartridge has demonstrated melphalan removal of greater than 98% during drug infusion in an in vivo study.
"Additionally the new filter removed significantly fewer blood platelets in the same study," Hobbs added.
"We look forward to the first European commercial procedure using the new filter, which is scheduled for next week."